Author's note: I had been contemplating writing this blog post for a while but for whatever reason had many stops and starts over many months.
Why the Results Are So Interesting
What makes psychedelic-assisted therapy so interesting to me is not just that the topic is new or unusual. It is the magnitude of the results. In many areas of mental health treatment, progress can be slow, incremental, and incomplete. A medication may help a patient feel somewhat better, or therapy may reduce symptoms over time, but full remission can be difficult to achieve, especially for conditions such as PTSD, addiction, or severe depression.
That is why some of the psychedelic studies are so compelling. The results are not just small improvements on a symptom scale. In several studies, a large percentage of participants no longer met the diagnostic criteria for the condition being treated. That is a very different type of outcome.
MDMA-Assisted Therapy for PTSD
The strongest evidence so far appears to be for MDMA-assisted therapy for PTSD. PTSD is notoriously difficult to treat, especially when it has lasted for years or decades. Many patients try medications, therapy, or both and still continue to suffer from nightmares, hypervigilance, anxiety, depression, avoidance, and difficulty functioning in daily life. That is what makes the MDMA data so remarkable.
In a 2021 Phase 3 trial published in Nature Medicine, 90 participants with severe PTSD were randomized to receive either MDMA-assisted therapy or placebo with therapy. The study measured PTSD symptoms using the CAPS-5, which is the Clinician-Administered PTSD Scale for DSM-5 and is commonly used to assess PTSD severity.
The results were striking. Participants in the MDMA-assisted therapy group had a much larger reduction in PTSD symptoms than those in the placebo-with-therapy group. Even more importantly, 67% of participants who received MDMA-assisted therapy no longer met the diagnostic criteria for PTSD, compared with 32% in the placebo group.
To me, that is the key point. The study was not simply saying patients felt a little better. Two-thirds of the participants receiving MDMA-assisted therapy no longer met the criteria for PTSD. For a condition that can destroy someone’s quality of life for decades, that is a major result.
A second Phase 3 study, published in Nature Medicine in 2023, was also impressive. This study included 104 participants with moderate to severe PTSD. By the end of the study, 86.5% of participants in the MDMA-assisted therapy group had a clinically meaningful response, and 71.2% no longer met DSM-5 criteria for PTSD. In the placebo-with-therapy group, 69% had a clinically meaningful response, and 47.6% no longer met PTSD criteria.
The placebo group also improved, which matters. It shows that the therapy itself was powerful. But the MDMA group improved more. The most important takeaway is that MDMA-assisted therapy is not simply a drug experience. It appears to work through the combination of the medicine, preparation, a therapeutic setting, and integration afterward.
That is part of what makes this treatment model so different from traditional psychiatry. Instead of taking a pill every day indefinitely, patients go through a limited number of highly structured sessions designed to help them process trauma in a different way.
The Durability of MDMA Results
Another reason the MDMA data interest me is the possibility that the benefits may last. Many psychiatric medications work only as long as the patient continues taking them. If the medication is stopped, symptoms may return.
MDMA-assisted therapy is being studied differently. It is not intended to be taken every day. It is used in a small number of therapeutic sessions. That makes durability extremely important.
A long-term follow-up study of MDMA-assisted psychotherapy for PTSD found that PTSD symptoms were reduced one to two months after treatment and that symptom improvement continued at least 12 months after treatment. Another review summarizing earlier MDMA-assisted therapy studies noted that the treatment effect appeared durable at one year and that, at nearly four years, many participants still no longer met PTSD criteria.
If results like that hold up in larger studies, the economic and human impact could be enormous. A treatment that produces durable improvement after a limited number of sessions is very different from a treatment that requires lifelong medication management.
Psilocybin and Smoking Cessation
The results for psilocybin and smoking cessation are also fascinating because smoking addiction is so difficult to treat. Many people try to quit multiple times using nicotine patches, gum, medications, or counseling, only to relapse.
A 2014 Johns Hopkins pilot study led by Matthew Johnson looked at psilocybin-assisted therapy for smoking cessation. The study was small, with only 15 participants, and it was open-label, meaning there was no placebo control group. So the results should not be overstated. But the magnitude of the results was hard to ignore.
At six months, 80% of participants were abstinent from smoking. A later long-term follow-up study found that 67% of participants were confirmed as smoking abstinent at 12 months, and 60% were confirmed as abstinent at long-term follow-up.
Those are unusually high numbers for smoking cessation. What interests me is not just that people quit smoking, but that the treatment seemed to help people change their relationship to the addiction. This is one of the themes that comes up repeatedly in psychedelic research: people often describe gaining a new perspective on destructive patterns that previously felt impossible to break.
More recently, a 2026 JAMA Network Open pilot randomized clinical trial compared psilocybin-assisted treatment with nicotine patch treatment. Both groups received cognitive behavioral therapy. At six months, 17 participants in the psilocybin group had biochemically verified prolonged abstinence, compared with 4 participants in the nicotine patch group.
Again, this does not mean psilocybin is a magic cure. But when a treatment produces results that appear meaningfully better than a standard comparison, it deserves serious attention.
Psilocybin and Alcohol Use Disorder
Psilocybin has also been studied for alcohol use disorder, another condition where relapse is common and long-term recovery can be difficult.
In a 2022 randomized clinical trial published in JAMA Psychiatry, 93 participants with alcohol use disorder received either psilocybin-assisted psychotherapy or an active placebo combined with psychotherapy. The study followed participants for 32 weeks.
The results showed that participants who received psilocybin had a much greater reduction in heavy drinking days than participants in the placebo group. NYU Langone summarized the study by reporting that two doses of psilocybin combined with psychotherapy reduced heavy drinking by 83% on average.
This is important because the study was not merely measuring whether participants felt more hopeful or had a meaningful experience. It measured actual behavior. People drank less. That is the type of result that matters clinically, economically, and socially.
Alcohol use disorder does not just affect the person drinking. It affects spouses, children, employers, friends, and communities. If psilocybin-assisted therapy can meaningfully reduce heavy drinking for even a portion of patients, the ripple effects could be significant.
Ibogaine and Trauma-Related Symptoms
Ibogaine may be even more complicated, but the early results are hard to ignore. Ibogaine has attracted attention for its potential role in addiction, trauma, traumatic brain injury, depression, and anxiety. It also has a more serious safety profile than psilocybin, particularly because of possible cardiac risks, so this is not something that should be viewed casually or outside medical supervision.
A Stanford-affiliated study published in Nature Medicine examined ibogaine treatment in 30 U.S. special operations veterans with histories of traumatic brain injury and repeated combat or blast exposure. Stanford Medicine summarized the findings by explaining that ibogaine treatment was associated with major improvements in disability, PTSD, depression, anxiety, and cognitive functioning.
The study was not randomized and did not include a placebo control group, which is a major limitation. However, the symptom reductions were very large. One month after ibogaine treatment, participants experienced average reductions of 88% in PTSD symptoms, 87% in depression symptoms, and 81% in anxiety symptoms.
What makes this especially meaningful is the population being studied. These were not people with mild symptoms. These were special operations veterans with significant trauma histories, and many had likely tried other approaches before seeking ibogaine.
Because the study was small and uncontrolled, it cannot prove that ibogaine caused all of the improvement. But the size of the symptom reductions makes the findings very difficult to dismiss. At a minimum, ibogaine appears to deserve more rigorous study.
Why These Results Could Matter Economically
The economic side is another reason I find this area so interesting. Mental health conditions are not only personally devastating; they are also expensive. PTSD, depression, addiction, and anxiety can lead to emergency room visits, hospitalizations, disability, unemployment, lost productivity, incarceration, family breakdown, and years of ongoing care.
This is where psychedelic-assisted therapy could potentially be different. The upfront treatment cost is high, but the treatment is limited in duration. For MDMA-assisted therapy, the total cost has been estimated around $11,000 to $15,000 per patient because the protocol requires preparation sessions, dosing sessions, and integration sessions. Therapists may spend 30 to 40 hours with each patient, and often two therapists are involved.
That sounds expensive. But if the treatment produces durable remission or major symptom reduction, it may actually save money over time.
One cost-effectiveness analysis published in PLOS ONE estimated that MDMA-assisted therapy for severe or extreme chronic PTSD could be cost-saving from a payer’s perspective while delivering substantial clinical benefit. A MAPS Bulletin article summarizing the economic research stated that MDMA-assisted therapy could save the health care system approximately $47,000 per patient over a 10-year horizon.
A later analysis estimated that treating 1,000 patients could generate approximately $132.9 million in discounted net health care savings over 30 years, while also producing gains in quality-adjusted life years and reducing premature deaths.
That is what makes the economics so compelling. The question is not whether psychedelic therapy is cheap upfront. The other issue as well is if insurance companies would cover this treatment especially if the payout takes many years and individuals are switching health insurance plans each year. However, Medicare would be different given once you are 65 the coverage is until you pass away (the economics there would make more sense). The question is whether it can reduce decades of downstream costs by helping people recover more fully and more durably.
The Challenge of Scaling the Results
The results are exciting, but they also create a practical problem: how would the system actually deliver this treatment if demand increased?
Psychedelic-assisted therapy is not easy to scale. It is not like writing a prescription and having a patient pick it up at a pharmacy. The treatment often requires preparation, a long dosing session, and integration afterward. One or two therapists may need to stay with a patient for six to twelve hours during the dosing session.
That means the bottleneck may not only be FDA approval. It may be the number of trained therapists and facilitators.
Some estimates suggest that tens of thousands of therapists may need to be trained over the next decade if psychedelic-assisted therapy becomes broadly available. Right now, the number of trained practitioners is far lower than what would likely be needed.
Cost is also a major issue. A 2023 study on group psychedelic therapy estimated that group therapy could reduce clinician costs by 50.9% for MDMA-assisted therapy for PTSD and by 34.7% for psilocybin-assisted therapy for major depressive disorder. For MDMA-assisted therapy, that translated into estimated clinician cost savings of $3,467 per patient.
Oregon’s psilocybin program gives an early example of both the promise and the scaling challenge. The state’s Oregon Psilocybin Services program is one of the first regulated psilocybin access models in the United States. Early real-world data have been encouraging from a safety standpoint, but access remains limited because the model is labor-intensive.
Service centers can only handle so many clients because each session requires trained facilitators, physical space, preparation, and follow-up. Even if demand is high, the number of trained facilitators, available rooms, and session hours creates a natural ceiling.
My Overall View of the Results
My own view is that the results are strong enough to take psychedelic-assisted therapy seriously, but they should still be presented carefully. The most impressive results appear to be:
MDMA-assisted therapy for PTSD, where Phase 3 trials found that approximately 67% of participants receiving MDMA-assisted therapy no longer met diagnostic criteria for PTSD, and a later 2023 Phase 3 trial found that 71.2% no longer met DSM-5 criteria for PTSD.
Psilocybin-assisted therapy for smoking cessation, where a Johns Hopkins pilot study found 80% abstinence at six months and a long-term follow-up found 67% abstinence at twelve months.
Psilocybin-assisted therapy for alcohol use disorder, where a randomized clinical trial in JAMA Psychiatry found a major reduction in heavy drinking days.
Ibogaine treatment for trauma-related symptoms, where a Stanford-affiliated study in Nature Medicine found large one-month reductions in PTSD, depression, and anxiety symptoms among special operations veterans.
Ibogaine treatment has a great potential for people who suffer from abusing opioids. Almost 80,000 people in America die each year for abusing opioids. This study found that after a single ibogaine treatment 50% of people had a reduction in cravings for opioids after 1 week and that declined over time. The interesting point is they found almost 50% of people who abstained were able to be abstinent for 1 years and 33% were able to abstain for 2 years.
Even more recently ibogaine in a case report showed improvement for a 52 year old woman with Parkinson's disease. She received a gradual increase of ibogaine and after 4 weeks had more energy, improved gait,
What stands out to me is that these are not minor improvements. In several cases, the studies show large changes in symptoms, behavior, or diagnostic status after a limited number of treatment sessions.
At the same time, the limitations matter. Some studies are small. Some are difficult to blind. Some lack placebo control groups. Some need longer follow-up. The FDA has also requested more data before approving MDMA-assisted therapy.
Even with those limitations, I believe the results are too significant to ignore. If future studies confirm these findings, psychedelic-assisted therapy could become one of the most important developments in mental health treatment in many decades.
